We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

The mother of a six-year-old girl with a rare neurodegenerative disease has urged health bosses to "do the right thing" amid ...

BioMarin's has signed the first contract with an insurer in Germany for Roctavian, its recently approved gene therapy for haemophilia A, as it tests out its outcomes-based agreement (OBA ...

Net income was up a robust 525% year over year, rising to $125 million. BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results. BioMarin Pharmaceutical ...

The upcoming report from BioMarin Pharmaceutical (BMRN) is expected to reveal quarterly earnings of $0.73 per share, indicating an increase of 49% compared to the year-ago period. Analysts ...

On Monday, Oppenheimer analysts raised their outlook on BioMarin Pharmaceutical (TADAWUL:2070) Inc. (NASDAQ:BMRN) stock, upgrading it from Perform to Outperform and setting a price target of $98.00.

BioMarin Pharmaceutical (NASDAQ:BMRN), a leader in developing innovative therapies for rare genetic disorders, reported fourth-quarter 2024 financial results on Wednesday, Feb. 19, that topped ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...